Immix Biopharma, Inc.
IMMX
$2.03
-$0.065-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.69% | 50.75% | 87.16% | 88.89% | 84.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.48% | 58.40% | 74.53% | 104.15% | 96.39% |
| Operating Income | -40.48% | -58.40% | -74.53% | -104.15% | -96.39% |
| Income Before Tax | -39.10% | -54.77% | -68.25% | -96.10% | -89.42% |
| Income Tax Expenses | 55.30% | 62.29% | 83.78% | 115.83% | 156.31% |
| Earnings from Continuing Operations | -39.13% | -54.79% | -68.28% | -96.14% | -89.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -49.85% | 45.66% | 429.95% | 1,113.04% | -- |
| Net Income | -40.11% | -54.85% | -67.00% | -94.14% | -87.44% |
| EBIT | -40.48% | -58.40% | -74.53% | -104.15% | -96.39% |
| EBITDA | -40.32% | -58.33% | -74.47% | -104.12% | -96.37% |
| EPS Basic | 11.08% | 7.18% | -5.20% | -37.37% | -48.65% |
| Normalized Basic EPS | 10.79% | 7.26% | -4.64% | -36.49% | -47.63% |
| EPS Diluted | 11.08% | 7.18% | -5.20% | -37.37% | -48.65% |
| Normalized Diluted EPS | 10.79% | 7.26% | -4.64% | -36.49% | -47.63% |
| Average Basic Shares Outstanding | 60.49% | 68.38% | 63.08% | 41.75% | 24.75% |
| Average Diluted Shares Outstanding | 60.49% | 68.38% | 63.08% | 41.75% | 24.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |